Evidence map›Paper›PMID 37745416›Full record

ArticlebioRxiv : the preprint server for biology2023

Cas13d-mediated isoform-specific RNA knockdown with a unified computational and experimental toolbox.

Megan D Schertzer, Andrew Stirn, Keren Isaev, Laura Pereira, Anjali Das, Claire Harbison, Stella H Park, Hans-Hermann Wessels, Neville E Sanjana, David A Knowles

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Megan D SchertzerNew York Genome Center, New York, NY.
Andrew StirnNew York Genome Center, New York, NY.
Keren IsaevNew York Genome Center, New York, NY.
Laura PereiraNew York Genome Center, New York, NY.
Anjali DasNew York Genome Center, New York, NY.
Claire HarbisonNew York Genome Center, New York, NY.
Stella H ParkNew York Genome Center, New York, NY.
Hans-Hermann WesselsNew York Genome Center, New York, NY.
Neville E SanjanaNew York Genome Center, New York, NY.
David A KnowlesNew York Genome Center, New York, NY.
New York Genome Center · US

Funding

In situ functional genomics to understand transcriptional regulationDP2HG010099 · NHGRI · NEW YORK GENOME CENTER · PI SANJANA, NEVILLE · 2017 to 2022
$4.4M
Enhancing Susceptibility of HIV Reservoirs to CTL Through a Discovery to Translational ApproachR01AI176601 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI R. Brad Jones, Neville Sanjana · 2023 to 2026
$3.3M
LTBR CARs as next-generation therapies for R/R lymphomaR01CA279135 · NCI · NEW YORK GENOME CENTER · PI Catherine Sibyl Diefenbach, Neville Sanjana · 2023 to 2026
$3.2M
A CRISPR/Cas13 approach for identifying individual transcript isoform function in cancerR21CA272345 · NCI · NEW YORK GENOME CENTER · PI KNOWLES, DAVID ARTHUR · 2022 to 2023
$699k
Measuring allele and isoform-specific RBP binding to improve predictive models of RNA splicingF32GM142213 · NIGMS · NEW YORK GENOME CENTER · PI SCHERTZER, MEGAN · 2021 to 2022
$134k
NCI NIH HHS R01 CA279135NCI NIH HHS R21 CA272345NHGRI NIH HHS DP2 HG010099NIAID NIH HHS R01 AI176601NIGMS NIH HHS F32 GM142213
6 · The paper itself

Abstract

Alternative splicing is an essential mechanism for diversifying proteins, in which mature RNA isoforms produce proteins with potentially distinct functions. Two major challenges in characterizing the cellular function of isoforms are the lack of experimental methods to specifically and efficiently modulate isoform expression and computational tools for complex experimental design. To address these gaps, we developed and methodically tested a strategy which pairs the RNA-targeting CRISPR/Cas13d system with guide RNAs that span exon-exon junctions in the mature RNA. We performed a high-throughput essentiality screen, quantitative RT-PCR assays, and PacBio long read sequencing to affirm our ability to specifically target and robustly knockdown individual RNA isoforms. In parallel, we provide computational tools for experimental design and screen analysis. Considering all possible splice junctions annotated in GENCODE for multi-isoform genes and our gRNA efficacy predictions, we estimate that our junction-centric strategy can uniquely target up to 89% of human RNA isoforms, including 50,066 protein-coding and 11,415 lncRNA isoforms. Importantly, this specificity spans all splicing and transcriptional events, including exon skipping and inclusion, alternative 5' and 3' splice sites, and alternative starts and ends.

Identifiers

PMID37745416
PMCPMC10515814
OpenAlexW4386745412

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.